Article

Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in <i>MET</i> exon 14 skipping mutation positive lung cancer

2018-07-22

Abstract excerpt

<h4>PURPOSE</h4> While patients with advanced-stage non-small cell lung cancers (NSCLCs) harboring MET exon 14 skipping mutations ( METex 14) often benefit from MET tyrosine kinase inhibitor (TKI) treatment, clinical benefit is limited by primary and acquired drug resistance. The molecular basis for this resistance remains incompletely understood. <h4>METHODS</h4> Targeted sequencing analysis was performed on...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b9a64945-a336-5446-8b1f-8c37e6e358fd
DOI: 10.1101/374181

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in <i>MET</i> exon 14 skipping mutation positive lung cancerDOI 10.1101/374181Read

Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung CancerSemantic proximity Read

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective StudySemantic proximity Read

Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non–Small-Cell Lung Cancer Harboring MET Exon 14 SkippingSemantic proximity Read

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung CancerSemantic proximity Read

Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers With Different MET Exon 14 Skipping Mutations.Semantic proximity Read

MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutationsSemantic proximity Read

From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skippingSemantic proximity Read

Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome SequencingSemantic proximity Read

Real-world analysis of MET exon 14 mutations in non-small cell lung cancer: a retrospective study from two Swedish hospitals.Semantic proximity Read

Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.Semantic proximity Read

Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer.Semantic proximity Read

Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinibSemantic proximity Read